Alexandra-Chloe Villani

Has grant

Principal Investigator, Director CIID Single Cell Genomics Research Program

Massachusetts General Hospital
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Improving immunotherapy outcomes through solving irAEs

Open Date: 2021-06-01

Close Date: 2024-05-31

Grant: Close

Single-cell genomics dissection of common immune networks driving autoimmunity

Open Date: 2021-01-01

Close Date: 2024-09-30

Articles (7)

Year:

2026

In growing bones of mice, multiple cell types contribute to the osteoblast lineage, including growth plate chondrocytes, perichondrial cells and CXCL12-abundant reticular marrow stromal cells. Here we use single-cell RNA sequencing and lineage tracing to show that all these osteoblast precursors, even postnatally, derives from Sox9-expressing progenitors. We also characterize a distinct group of chondrocytes located between the perichondrium and the columns of growth plate chondrocytes that contribute to the osteoblast lineage.

Year:

2025

Introduction Immune checkpoint inhibitor-associated acute interstitial nephritis (ICI-AIN) is the most common finding on histopathology among patients with ICI-associated acute kidney injury (ICI-AKI). Patients with ICI-AIN often have T cell-dominant infiltration of the kidney and high tissue levels of CXCR3 ligands like CXCL9, 10, and 11; however, the mechanisms of inflammation in ICI-AIN are not well-understood. Methods We applied a sub-cellular spatial transcriptomics platform (Xenium Prime 5K) to compare the cellular composition of kidney biopsy tissue from patients with ICI-AIN with ICI-treated patients with acute tubular necrosis (ICI-ATN). Results Across 8 kidney biopsy specimens (4 with ICI-AIN, 4 with ICI-ATN), we analyzed 332,000 cells, comprising kidney parenchymal cells and infiltrating immune cells. Using a spatially-aware cellular neighborhood-based classification, we identified cellular niches corresponding to each part of the nephron, in addition to unique fibrotic and inflammatory niches. Gene pathway analysis identified interferon-gamma (IFN-γ)/STAT1 signaling as strongly increased in ICI-AIN compared to ICI-ATN. While all inflammatory niches were overrepresented in ICI-AIN, CD8 + T cell infiltration and proinflammatory myeloid cells were the dominant immune niches. Spatial niche crosstalk analysis revealed that CD8 + T cell-derived IFN-γ likely induced a proinflammatory program in myeloid cells, with increased production of CXCL9, 10, and 11. Furthermore, IFN-γ signaling in ICI-AIN was associated with reduced oxidative phosphorylation in kidney tubular niches. Conclusions Spatial transcriptomics reveal novel insights into key differences in the pathophysiology of ICI-AIN versus ICI-ATN. IFN-γ-producing CD8 + T cells are likely key drivers of ICI-AIN and should be investigated as future therapeutic targets. Translational Statement Spatial transcriptomics may provide insight into differences in the cellular and spatial composition of immune checkpoint inhibitor-associated acute interstitial nephritis (ICI-AIN) and ICI-associated acute tubular necrosis (ICI-ATN). Using the novel Xenium 5K platform, we demonstrate that IFN-γ-producing CD8 + T cells are central to the pathogenesis of ICI-AIN, and that CD8 + T cell-derived IFN-γ likely induces a proinflammatory state in myeloid cells, with increased tissue production of CXCL9, 10, and 11. We then show that a reduction in oxidative phosphorylation and an IFN-γ-driven influx of proinflammatory myeloid cells may further drive kidney damage in ICI-AIN. Many of these pathways represent potential druggable targets, and our findings may therefore inform future therapeutic approaches for ICI-AIN.

Year:

2025

The alpha-variant wave of the COVID-19 pandemic provided a unique opportunity to study, at single-cell resolution, how near-universal exposure to the same pathogen can lead to either effective or dysfunctional immune responses in humans. Although single-cell RNA-sequencing studies have characterized immune cellular features of COVID-19, they have not shown how tocilizumab treatment changes these features at single-cell resolution, or which features might persist into convalescence. In this study, we analyzed 2.5 million circulating immune cells from 428 patients across time points (840 PBMC samples), encompassing three contemporaneous SARS-CoV-2 cohorts: acutely infected patients across five WHO disease severity levels and three time points, patients from the first randomized control trial to study the efficacy of tocilizumab in the management of COVID-19, and convalescent patients three months after infection. We used linear modeling to integrate multiple data types – including single-cell RNA-seq, CITE-seq, TCR and BCR sequencing, viral load measurements, viral neutralization assays, detection of 75 autoantibodies, HLA genotype data, and serum proteomics covering 1,463 targets – to derive the most comprehensive view to-date of the biological features of COVID-19 disease severity. Our findings show that myeloid-derived suppressor cells (MDSCs) act as a key immunologic pivot point in severe COVID-19. Myeloid dysfunction, which is marked by impaired antigen presentation, drives a non-productive adaptive immune response, as reflected by reduced expression of B and T cell gene programs involved in antigen recognition, immune synapse formation, and cytotoxicity. Severe disease is also linked to autoantibodies targeting type I interferons, influenced by specific HLA-DQB1 allelic variants, and strongly correlated with serum IL-6 levels. Tocilizumab treatment eliminates CLU -expressing MDSCs and ISG-positive myeloid subsets, restores antigen presentation, and reactivates productive adaptive immunity. These changes align with improved clinical outcomes and better clinical laboratory measures, including reduced CRP. While many immunologic abnormalities in acute severe COVID-19 resolve during convalescence 3-months post-infection, we observed persistently high ICOS expression in regulatory T cells, potentially linking acute infection to chronic post-COVID syndromes. Overall, we define distinct innate and adaptive host immune responses associated with acute, IL-6–responsive, and convalescent SARS-CoV-2 infection. Our multimodal and high-dimensional dataset with curated clinical metadata provides a foundational and clinically relevant resource for modeling host immune response biology in health and disease.

Year:

2025

Single-cell techniques allow concurrent study of gene activity and T cell receptor (TCR) sequences, identifying connections between TCR structure and cell traits. Expanding on our CoNGA software, we present a “metaCoNGA” analysis of 6 million T cells from 91 diverse studies, mapping TCR sequence similarity across tissues and diseases. This approach exposes shared TCR features within specific T cell subsets, including those associated with infection, cancer, and autoimmunity. We introduce a method to identify T cell groups with similar gene expression and biased TCR amino acid composition, providing a systematic framework for classifying diverse unconventional T cells, including KIR+ CD8+ T cells, CD4+ regulatory T cells, and subsets of NKT and MAIT cells. A new TCR clustering approach identifies thousands of convergent TCR sequence clusters hypothesized to target shared antigens. These clusters show coherent gene expression, highlighting the role of antigen exposure in shaping T cell behavior. Finally, we provide a tool for users to merge new data with this resource and rapidly identify T cell features in their data sets. This resource empowers investigations into the complex relationship between TCR sequence and T cell function in human health.

Year:

2025

Background T cells play a central role in host protection against respiratory pathogens, but a maladaptive T cell response can lead to pulmonary diseases. Defining the biology of protective versus pathogenic T cell responses in the lungs of humans will be critical to nominate novel approaches to improve respiratory health. Previous studies have examined T cells from the lungs captured via bronchoalveolar lavage (BAL), endobronchial brushings, or biopsies. However, whether these different approaches are capturing distinct T cell phenotypes and/or clonotypes remains unclear. Objective To evaluate and compare the transcriptional signatures of T cells isolated via BAL versus endobronchial brushings in healthy controls (HCs) and allergic asthmatics (AAs). Methods Flexible bronchoscopy was performed to obtain BAL and endobronchial brushings from 3 HC and 3 AA subjects. CD3+ T cells were sorted and single cell RNA- and T cell receptor (TCR)-sequencing was performed using the 10X Chromium platform. Unbiased clustering, differential gene expression analysis and TCR repertoire analysis was performed. Results Unbiased clustering analysis allowed us to define 7 CD8 and 6 CD4 T cell subsets. The most significant difference in T cell subsets abundance between AAs and HCs was the enrichment of CD4 T helper type 2 (Th2) cells when comparing endobronchial brush samples (OR=26.2, P=0.002), but not when examining BAL (OR=1.7, P=0.46), indicating differences in the T cell subsets captured from the BAL versus airway mucosa specimen processing. In further support of this observation, comparing the BAL and brush T cells across all subjects revealed an up-regulation of resident-memory T cell markers (i.e. ITGAE, CD69 ) in brush T cells versus BAL T cells in both CD4 and CD8 lineages. In contrast, BAL CD8 and CD4 T cells exhibited an enriched type I and II interferon signatures compared to brush T cells. Lastly, TCR repertoire analysis revealed that brush T cells contained dramatically expanded TCR clones. Expanded T cell clones from the brush expressed high levels of resident-memory markers, suggesting the airway mucosa is enriched for T RM cells with unique TCR specificity. Conclusions Sampling T cells via BAL versus airway brushings yielded distinct T cell phenotypes and clonotypes with important implications for future research in lung immunology.

Year:

2025

Thyroid hormone, produced in the thyroid gland, regulates metabolism, development, and cardiac function. The thyroid is susceptible to autoimmune attack by both cellular and humoral immunity exemplified by Hashimoto’s thyroiditis (HT) and Graves’ Disease (GD), respectively. In HT, immune-mediated destruction impairs thyroid hormone production, while in GD, stimulating autoantibodies promote over-production. Here, we generated a multi-modal atlas of 604,076 human thyroid and blood cells from HT, GD, and control patients. We found that, despite markedly different clinical presentations and distinct antigenic triggers, HT and GD exhibit convergent cellular dynamics resulting in a shared continuum of immune infiltration. Along this continuum, a key feature is a thyrocyte niche containing CD8 + T cells that may segregate pathogenic T cells from regions with preserved thyroid hormone production. These findings of a shared disease continuum characterized by spatially defined immune niches provide a new framework for understanding tissue homeostasis in human autoimmune disease.

Year:

2025

Collaborators (25)

Andrew Luster

Professor

Massachusetts General Hospital

UNITED STATES
View details

Joseph J Zhao

National University of Singapore

SINGAPORE
View details

Anastasia Minervina

Staff Scientist

Fred Hutch Cancer Center

UNITED STATES
View details

Miguel Reyes

Senior Scientist

Genentech Inc

UNITED STATES
View details

Raghav Sundar

Associate Professor

Yale University

UNITED STATES
View details

Marcia Goldberg

Harvard University

UNITED STATES
View details

Elad Sharon

Associate Professor

Harvard University

UNITED STATES
View details

Deepak Rao

Associate Professor of Medicine

Brigham and Women's Hospital

UNITED STATES
View details

Novalia Pishesha

Broad Institute

UNITED STATES
View details

Genevieve Boland

Chair of Surgery

Medical College of Wisconsin

UNITED STATES
View details

Michael Drage

Assistant Professor

Massachusetts General Hospital

UNITED STATES
View details

Philip Bradley

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Matthew Strickland

Harvard University

UNITED STATES
View details

Iwijn De Vlaminck

Professor

Cornell University

UNITED STATES
View details

Gary Reynolds

Massachusetts General Hospital

UNITED STATES
View details

Kasi Vegesana

Data Scientist

St. Jude Children's Research Hospital

UNITED STATES
View details

Astrid Weins

Assistant Professor

Brigham and Women's Hospital

UNITED STATES
View details

Dennis Moledina

Associate Professor and Chief of Nephrology

Rutgers University

UNITED STATES
View details

William Hazelton

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Paul G Thomas

Professor

Fred Hutch Cancer Center

UNITED STATES
View details

Benjamin Medoff

Massachusetts General Hospital

UNITED STATES
View details

Betsabeh Khoramian Tusi

Staff Scientist

Harvard University

UNITED STATES
View details

Molly Thomas

Assistant Professor

Oregon Health & Science University

UNITED STATES
View details

Peter Sadow

Director, Head & Neck Pathology

Harvard Medical School

UNITED STATES
View details

Rod Rahimi

Assistant Professor

Massachusetts General Hospital

UNITED STATES
View details